cholesterol drug news from FierceBiotech
NewsMerck shelves study of cholesterol drug
Saying it had the wrong patient population, Merck has discontinued its ACHIEVE imaging study for its cholesterol drug MK-0524A. Its steering committee recommended a new imaging study that included a Read more...
Analyst predicts a long delay for Merck's Cordaptive
There's more bad news--or analysis--for Merck's drug development efforts. After the FDA Read more...
Merck shares hammered after FDA rejects Cordaptive
Shares of Merck were sliding again this morning on the news that the FDA has turned thumbs down on MK-0524A, its new cholesterol therapy. The stock dropped eight percent after regulators announced Read more...
SPOTLIGHT: Merck halts trial enrollment
Merck's giant migraine over the Vytorin data is spilling into one of its development programs. Researchers halted enrollment in a late-stage study of the cholesterol drug Cordaptive to ponder Read more...
Safety, efficacy problems sink Takeda drug
Japan's Takeda has walked away from development of its once-promising cholesterol drug TAK-475. The first sign of Read more...
Full speed ahead for Vytorin II at Merck, Schering
The disastrous results of the recent Vytorin study have apparently done nothing to blunt the appetites Read more...
ALSO NOTED: Big Pharma rethinks animal testing; FDA extends telavancin review; and much more...
> In a move that will please animal rights activists, a number of pharmaceutical companies have determined that they will no longer conduct acute toxicity tests. They say that new technology has Read more...
Genzyme wins Isis pact with $1.9B bid
Shares of Isis Pharmaceuticals rocketed up 45 percent after the biotech announced that Genzyme had signed on as a partner to Read more...
ALSO NOTED: Savient shares soar on trial results; Pharming handed a rejection on Rhucin;ARCH closes $400M VC fund; and much mor
> It wasn't all bad news on Wall Street. Shares of Savient jumped almost 50 percent after researchers announced that its experimental gout therapy, Puricase, met the main goal of a late-stage Read more...
| Press ReleasesPRESS RELEASE: Younger Adults Increasingly Treated for Heart Disease-related Conditions Younger Adults Increasingly Treated for Heart Disease-related Conditions Increase in use of cholesterol and hypertension medications largest among people ages 20 to 44 Drop in the age of women using Read more... |
Get more cholesterol drug coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends